Arena Investors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Arena Investors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-43,451	Closed	-$5.03M	–	52
2023 Q3	$5.03M	Hold	43,451	–	–	5.67%	3
2023 Q2	$4.47M	Sell	43,451 -36,540	-46%	-$3.86M	3.93%	6
2023 Q1	$8.73M	Buy	79,991 +54,933	+219%	+$6.07M	6.76%	4
2022 Q4	$2.85M	Buy	+25,058	New	+$2.08M	2.64%	11

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Arena Investors's HZNP Position: Q4 2023 in Review

Arena Investors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 43,451 shares — an estimated $5.03M sold.

Arena Investors first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $8.73M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Arena Investors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Arena Investors sold 43,451 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $5.03M.
Arena Investors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
Arena Investors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8.73M in Q1 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Arena Investors's 13F filing for Q4 2023, filed 14 Feb 2024.